Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE versus LINCOMYCIN HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE versus LINCOMYCIN HCL.
CLINDAMYCIN PHOSPHATE vs LINCOMYCIN HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, inhibiting peptide bond formation and translocation.
600 mg IV every 8 hours or 300-450 mg PO every 6 hours
600 mg IM every 12-24 hours or 600 mg IV every 8-12 hours, up to 8 g/day for severe infections.
None Documented
None Documented
Terminal half-life 2-4 hours (prolonged to 8-12 hours in severe hepatic impairment; unchanged in renal failure)
4-5 hours (prolonged in renal impairment, up to 10 hours in anuria; no significant change in hepatic disease).
Renal 10% unchanged, fecal/biliary 90% as metabolites (mostly inactive)
Renal (approximately 40% unchanged in urine) and biliary/fecal (approximately 50% as active drug and metabolites).
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic